---
title: "SGLT2 inhibitors: mechanisms, physiology, pharmacology, and clinical applications"
id: "pubmed-42814168"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42814168"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42814168/"
doi: "10.1186/s43556-026-00604-3"
published_at: "2026-09-30T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# SGLT2 inhibitors: mechanisms, physiology, pharmacology, and clinical applications
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42814168
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42814168/)
- **DOI:** [10.1186/s43556-026-00604-3](https://doi.org/10.1186%2Fs43556-026-00604-3)
- **Published At:** 2026-09-30T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- **SGLT2** is a low-affinity, high-capacity sodium–glucose cotransporter primarily expressed in the renal proximal tubule and is responsible for most filtered glucose reabsorption. - **SGLT2 inhibitors** block proximal tubular glucose reabsorption, producing glycosuria and osmotic diuresis and altering renal haemodynamics via restoration of tubuloglomerular feedback. - Early renal and circulatory changes after SGLT2 inhibition include altered fluid compartmentalisation and resetting of renal haemodynamics that interact with systemic metabolic adaptations. - Systemic adaptations associated with SGLT2 inhibition noted in the source include pseudo‑starvation signalling, increased erythropoiesis, changes in uric acid handling, and shifts in substrate availability. - At the cellular level, SGLT2 inhibition has been associated with improved ionic homeostasis, enhanced mitochondrial quality control, reduced oxidative stress, modulation of inflammation, and attenuation of maladaptive tissue remodelling. - Endothelial injury, microvascular dysfunction, fibrosis, and endothelial-to-mesenchymal transition (EndMT) are discussed as mechanistic links between cellular effects and clinical outcomes; EndMT is presented as one part of a broader endothelial–stromal stress response rather than a sole proven mediator. - The integrated pharmacodynamic and cellular effects underpin the consistent clinical efficacy of SGLT2 inhibitors across **type 2 diabetes**, **chronic kidney disease (CKD)**, and **heart failure (HF)**, and support exploration of emerging uses in acute HF, post‑myocardial infarction, arrhythmia, and metabolic dysfunction–associated steatohepatitis. - The Review identifies translational gaps and future directions: mechanism‑informed biomarkers, imaging and spatial multi‑omics, phenotype‑guided patient stratification, dual SGLT1/2 inhibition, and rational combination therapy. - Source metadata: review article published in Mol Biomed 2026; PMID 42814168; DOI 10.1186/s43556-026-00604-3. Authors declare no competing interests relevant to the article.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42814168/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42814168%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42814168/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42814168/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42814168/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42814168/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42814168/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42814168/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42814168%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42814168%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42814168/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42814168/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42814168/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42814168/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42814168/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42814168/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42814168/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42814168/#conflict-of-interest) * [ References ](https://pubmed.ncbi.nlm.nih.gov/42814168/#references) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42814168/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42814168/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42814168/#substances) * [ Grants and funding ](https://pubmed.ncbi.nlm.nih.gov/42814168/#grants) Title & authors Abstract Conflict of interest statement References Publication types MeSH terms Substances Grants and funding Review Mol Biomed Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mol+Biomed%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Mol+Biomed%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814168/) . 2026 Sep 30;7(1):191. doi: 10.1186/s43556-026-00604-3. # SGLT2 inhibitors: mechanisms, physiology and pharmacology, and clinical applications [Xue-Ting Zheng](https://pubmed.ncbi.nlm.nih.gov/?term=Zheng+XT&cauthor_id=42814168)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#full-view-affiliation-1 "The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China."), [Hui-Yi Xie](https://pubmed.ncbi.nlm.nih.gov/?term=Xie+HY&cauthor_id=42814168)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#full-view-affiliation-1 "The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China."), [Xiu-Heng Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+XH&cauthor_id=42814168)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#full-view-affiliation-2 "The First Affiliated Hospital, Department of Endocrinology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China."), [Yue Zhao](https://pubmed.ncbi.nlm.nih.gov/?term=Zhao+Y&cauthor_id=42814168)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#full-view-affiliation-1 "The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China."), [Jia-Yan Yang](https://pubmed.ncbi.nlm.nih.gov/?term=Yang+JY&cauthor_id=42814168)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#full-view-affiliation-1 "The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China."), [Yun-Xi Liu](https://pubmed.ncbi.nlm.nih.gov/?term=Liu+YX&cauthor_id=42814168)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#full-view-affiliation-1 "The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China."), [Xian-Liang Yuan](https://pubmed.ncbi.nlm.nih.gov/?term=Yuan+XL&cauthor_id=42814168)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#full-view-affiliation-1 "The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China."), [Hui-Fang Tang](https://pubmed.ncbi.nlm.nih.gov/?term=Tang+HF&cauthor_id=42814168)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#full-view-affiliation-1 "The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China."), [Zhi-Sheng Jiang](https://pubmed.ncbi.nlm.nih.gov/?term=Jiang+ZS&cauthor_id=42814168)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#full-view-affiliation-1 "The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China."), [Heng-Jing Hu](https://pubmed.ncbi.nlm.nih.gov/?term=Hu+HJ&cauthor_id=42814168)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#full-view-affiliation-3 "The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China. bestmanhhj@hotmail.com.")[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#full-view-affiliation-4 "Department of Cardiovascular Disease and Key Laboratory for Atherosclerosis of Hunan Province, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China. bestmanhhj@hotmail.com.") Affiliations Expand ### Affiliations * 1 The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China. * 2 The First Affiliated Hospital, Department of Endocrinology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China. * 3 The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China. bestmanhhj@hotmail.com. * 4 Department of Cardiovascular Disease and Key Laboratory for Atherosclerosis of Hunan Province, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China. bestmanhhj@hotmail.com. * PMID: **42814168** * DOI: [ 10.1186/s43556-026-00604-3 ](https://doi.org/10.1186/s43556-026-00604-3) Item in Clipboard Review # SGLT2 inhibitors: mechanisms, physiology and pharmacology, and clinical applications Xue-Ting Zheng et al. Mol Biomed. 2026. Show details Display options Display options Format Abstract PubMed PMID Mol Biomed Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Mol+Biomed%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Mol+Biomed%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42814168/) . 2026 Sep 30;7(1):191. doi: 10.1186/s43556-026-00604-3. ### Authors [Xue-Ting Zheng](https://pubmed.ncbi.nlm.nih.gov/?term=Zheng+XT&cauthor_id=42814168)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#short-view-affiliation-1 "The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China."), [Hui-Yi Xie](https://pubmed.ncbi.nlm.nih.gov/?term=Xie+HY&cauthor_id=42814168)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#short-view-affiliation-1 "The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China."), [Xiu-Heng Wang](https://pubmed.ncbi.nlm.nih.gov/?term=Wang+XH&cauthor_id=42814168)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#short-view-affiliation-2 "The First Affiliated Hospital, Department of Endocrinology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China."), [Yue Zhao](https://pubmed.ncbi.nlm.nih.gov/?term=Zhao+Y&cauthor_id=42814168)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#short-view-affiliation-1 "The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China."), [Jia-Yan Yang](https://pubmed.ncbi.nlm.nih.gov/?term=Yang+JY&cauthor_id=42814168)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#short-view-affiliation-1 "The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China."), [Yun-Xi Liu](https://pubmed.ncbi.nlm.nih.gov/?term=Liu+YX&cauthor_id=42814168)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#short-view-affiliation-1 "The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China."), [Xian-Liang Yuan](https://pubmed.ncbi.nlm.nih.gov/?term=Yuan+XL&cauthor_id=42814168)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#short-view-affiliation-1 "The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China."), [Hui-Fang Tang](https://pubmed.ncbi.nlm.nih.gov/?term=Tang+HF&cauthor_id=42814168)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#short-view-affiliation-1 "The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China."), [Zhi-Sheng Jiang](https://pubmed.ncbi.nlm.nih.gov/?term=Jiang+ZS&cauthor_id=42814168)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#short-view-affiliation-1 "The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China."), [Heng-Jing Hu](https://pubmed.ncbi.nlm.nih.gov/?term=Hu+HJ&cauthor_id=42814168)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#short-view-affiliation-3 "The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China. bestmanhhj@hotmail.com.")[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42814168/#short-view-affiliation-4 "Department of Cardiovascular Disease and Key Laboratory for Atherosclerosis of Hunan Province, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China. bestmanhhj@hotmail.com.") ### Affiliations * 1 The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China. * 2 The First Affiliated Hospital, Department of Endocrinology, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China. * 3 The First Affiliated Hospital, Department of Cardiovascular Medicine, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China. bestmanhhj@hotmail.com. * 4 Department of Cardiovascular Disease and Key Laboratory for Atherosclerosis of Hunan Province, Hengyang Medical School, University of South China, Hengyang, Hunan, 421001, P.R. China. bestmanhhj@hotmail.com. * PMID: **42814168** * DOI: [ 10.1186/s43556-026-00604-3 ](https://doi.org/10.1186/s43556-026-00604-3) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract Sodium-glucose cotransporter 2 (SGLT2) is a low-affinity, high-capacity transporter expressed predominantly in the renal proximal tubule, where it mediates the sodium-coupled reabsorption of most filtered glucose. SGLT2 inhibitors have evolved from glucose-lowering agents into disease-modifying therapies across the cardio-renal-metabolic continuum. Blockade of proximal tubular transport induces glycosuria, osmotic diuresis, restoration of tubuloglomerular feedback, resetting of renal haemodynamics, and altered fluid compartmentalisation. These early renal and circulatory effects interact with systemic metabolic adaptations, including pseudo-starvation signalling, erythropoiesis, altered uric acid handling, and changes in substrate availability. At the cellular level, SGLT2 inhibition has been linked to improved ionic homeostasis and mitochondrial quality control, reduced oxidative stress, modulation of inflammation, and attenuation of maladaptive tissue remodelling. Endothelial injury may connect these cellular effects with microvascular dysfunction and fibrosis. Endothelial dysfunction and endothelial-to-mesenchymal transition (EndMT) offer a mechanistic framework for understanding the relationship between microvascular injury and fibrosis. However, EndMT is best viewed as one component of a broader endothelial-stromal stress response rather than as a single proven mediator of clinical benefit. These pharmacodynamic and cellular effects help explain the consistent clinical efficacy of SGLT2 inhibitors across type 2 diabetes, chronic kidney disease, and heart failure (HF), while also informing emerging applications in acute HF, after myocardial infarction, and in patients with arrhythmia or metabolic dysfunction-associated steatohepatitis. This Review integrates mechanistic, pharmacological, and clinical evidence to identify unresolved translational gaps and future directions, including mechanism-informed biomarkers, imaging, spatial multi-omics, phenotype-guided patient stratification, dual sodium-glucose cotransporter 1/2 inhibition, and rational combination therapy. **Keywords:** Cardio-renal-metabolic continuum; Chronic kidney disease; Endothelial-to-mesenchymal transition; Heart failure; Precision medicine; SGLT2 inhibitors. © 2026. The Author(s). [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors have no competing interests to declare that are relevant to the content of this article. ## References 1. 1. Chao EC, Henry RR. SGLT2 inhibition–a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551–9. . - [DOI](https://doi.org/10.1038/nrd3180) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/20508640/) 2. 1. Wright EM. SGLT2 inhibitors: physiology and pharmacology. Kidney360. 2021;2(12):2027–37. . - [DOI](https://doi.org/10.34067/kid.0002772021) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/35419546/) - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/8986039/) 3. 1. Preda A, Montecucco F, Carbone F, Camici GG, Lüscher TF, Kraler S, et al. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res. 2024;120(5):443–60. . - [DOI](https://doi.org/10.1093/cvr/cvae047) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/38456601/) - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/12001887/) 4. 1. Usman MS, Bhatt DL, Hameed I, Anker SD, Cheng AYY, Hernandez AF, et al. Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2024;12(7):447–61. . - [DOI](https://doi.org/10.1016/s2213-8587\(24\)00102-5) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/38768620/) 5. 1. Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on ki
## Related Clinical Research

- [Soluble urokinase plasminogen activator receptor (suPAR) across the kidney–cardiometabolic continu](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-soluble-urokinase-plasminogen-activator-receptor-across-the-kidney.md)
- [Comparing BMI, Waist Circumference, and BRI for Predicting ASCVD, AF, and Mortality in 1.2M Koreans](https://medichelpline.com/clinical-feed/plos-one-14-prognostic-associations-of-anthropometric-indices-with-major-health-outcomes-a.md)
- [Long-term cardiovascular risk after assisted reproductive technology and infertility: nationwide c](https://medichelpline.com/clinical-feed/plos-medicine-0-long-term-risk-of-cardiovascular-disease-after-assisted-reproductive-technology.md)
- [KERENDIA FDA Approval for CKD in Type 1 Diabetes and Arrowhead’s Plozasiran SHASTA-3/4 Phase 3 Res](https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-september-18-2026.md)
- [Cardiometabolic pathways mediating the effect of educational attainment on cardiovascular disease:](https://medichelpline.com/clinical-feed/medrxiv-13-cardiometabolic-pathways-linking-genetically-proxied-educational-attainment-to.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.